Sirtris Pharmaceuticals, Inc. - Current report filing (8-K)
March 26 2008 - 10:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported):
March 24, 2008
SIRTRIS
PHARMACEUTICALS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-51171
|
|
20-1410189
|
(State or other
jurisdiction
of incorporation
or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification
No.)
|
200
Technology Square, Cambridge, Massachusetts 02139
(Address of
Principal Executive Offices) (Zip Code)
Registrants
telephone number, including area code:
(617) 252-6920
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (
see
General Instruction A.2. below):
o
|
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o
|
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Officers; Compensatory
Arrangements of Certain Officers
Election of Directors
On March 24, 2008,
the Board of Directors of Sirtris Pharmaceuticals, Inc. (the Company),
upon recommendation from the Companys Nominating and Corporate Governance
Committee, voted to appoint Paul Friedman, M.D. as a director of the Company,
effective March 24, 2008. Dr. Friedman was elected to a term expiring
at the Companys 2009 Annual Meeting of Stockholders. Dr. Friedman was
appointed to the Compensation Committee. Dr. Friedman will receive fees
consistent with those fees received by the existing directors for service as a
director of the Company. A copy of the Companys press release announcing Dr. Friedmans
appointment is attached hereto as Exhibit 99.1 and the information contained
therein is incorporated herein by reference.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
99.1 Press Release issued by the Company
dated March 25, 2008.
2
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
Sirtris Pharmaceuticals, Inc.
|
|
|
Date: March 25, 2008
|
By:
|
/s/ Christoph Westphal
|
|
|
Name:
|
Christoph Westphal
|
|
|
Title:
|
President and Chief Executive Officer
|
|
|
|
|
|
3
EXHIBIT LIST
99.1 Press Release issued by the Company
dated March 25, 2008.
4
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Aug 2023 to Aug 2024